NiKang Therapeutics, Roche partner for advanced liver cancer treatment trial
NiKang Therapeutics Inc., a clinical-stage biotech company specializing in small molecule oncology medicines, has announced a significant clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (Roche). This partnership focuses on evaluating NiKang’s NKT2152, a novel small molecule that inhibits hypoxia-inducible factor 2α (HIF2α), in combination with Roche’s atezolizumab (Tecentriq) and bevacizumab (Avastin) […]